Lonza has announced it will expand its viral-based therapeutics business with the construction of a new, state-of-the-art cGMP clean room located adjacent to its existing Houston, Texas operations.
The clean room will benefit customers by offering large-scale capacity to support late-stage viral vaccine and gene therapy projects. It will utilize disposable process systems and be able to support production and fill/finish operations of up to 2,000 liters. Enhanced EU-compliant fill and finish capabilities are in high demand from Lonza's pharma and biotech customers. The expansion will also notably reduce Lonza's clients' wait times for clean room capacity due to the ability to run multiple GMP operations simultaneously.
"We are very pleased with the growing number of opportunities we are seeing in the viral vaccine and viral vector sector," said David Enloe, Head of Lonza's Viral-based Therapeutics unit. "This investment only furthers our commitment to a leadership position in this exciting space of new therapeutics and vaccines." Construction and validation of Lonza's viral expansion is expected to be completed in early 2012.
The Swiss sensor manufacturer Sensirion AG has launched the LG01 micro flow switch to detect ultra-low liquid flow rates or the presence of air in fluidic systems. The sensor increases reliability by enabling the detection of liquid flow within the range of a few ml/min and less. For such measurements the sensor offers a short response time below 100 ms. Its output signal of either 0 or 5 volts indicates whether the current flow rate is above or below the specified flow switch level. Maximum flow rates are accepted up to 220 ml/min.
The tiny, lightweight sensor is designed for integration into bio-medical applications and general process control solutions.